SAN DIEGO--(BUSINESS WIRE)--Jan. 7, 2019--
DexCom, Inc. (Nasdaq: DXCM), the leader in continuous glucose monitoring
(“CGM”), today reported that it expects preliminary, unaudited revenue
for the fourth quarter ended December 31, 2018 to exceed $331 million,
an increase of at least 50% over the fourth quarter of 2017. For fiscal
2018, total preliminary, unaudited revenue is expected to exceed $1.025
billion, an increase of more than 42% over 2017.
“We are thrilled with Dexcom’s full-year performance in 2018, with
growth exceeding our original expectations by a significant margin and
driving us to a historic milestone of more than $1 billion in annual
revenues. Our success in 2018 was driven by increasing awareness of the
importance of CGM in managing diabetes, supported by the approval and
launch of Dexcom’s G6 CGM platform both in the U.S. and
internationally,” said Kevin Sayer, Dexcom’s Chairman, President and
CEO. “Looking ahead to 2019, we are confident in our position to
continue delivering strong results.”
For 2019, Dexcom currently anticipates total revenue of approximately
$1.175 billion to $1.225 billion, representing expected growth of
approximately 15% to 20% over 2018. This growth outlook is driven by
strong growth in sensor volumes, continued international expansion,
shifting channel mix and overall market dynamics.
Dexcom will provide further details related to its 2019 financial
expectations on the fourth quarter earnings call.
Fourth Quarter 2018 Financial Results Conference Call
Dexcom will report its audited full fourth quarter and fiscal 2018
financial results on Thursday, February 21, 2019 after the close of
market. Management is currently scheduled to host a conference call at
4:30 p.m. (Eastern Time) that day. More details will be provided later.
About DexCom, Inc.
DexCom, Inc., headquartered in San Diego, California, is developing and
marketing continuous glucose monitoring systems for ambulatory use by
people with diabetes and by healthcare providers for the treatment of
people with diabetes.
Cautionary Statement Regarding Forward Looking Statements
This press release contains forward-looking statements that are not
purely historical regarding Dexcom’s or its management’s intentions,
beliefs, expectations and strategies for the future, including those
related to Dexcom’s expected revenue for the fourth quarter of and the
full fiscal year 2018, estimated revenue for fiscal 2019, expected 2019
growth in sensor volumes and international revenue. All forward-looking
statements and reasons why results might differ included in this press
release are made as of the date of this release, based on information
currently available to Dexcom, deal with future events, are subject to
various risks and uncertainties, and actual results could differ
materially from those anticipated in those forward-looking statements.
The risks and uncertainties that may cause actual results to differ
materially from Dexcom’s current expectations are more fully described
in Dexcom’s Annual Report on Form 10-K for the period ended December 31,
2017, as filed with the Securities and Exchange Commission on February
27, 2018, its most recent Quarterly Report on Form 10-Q for the period
ended September 30, 2018, as filed with the Securities and Exchange
Commission on November 6, 2018, and its other reports, each as filed
with the Securities and Exchange Commission. Except as required by law,
Dexcom assumes no obligation to update any such forward-looking
statement after the date of this report or to conform these
forward-looking statements to actual results.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190107005386/en/
Source: DexCom, Inc.
Steven R. Pacelli
Executive Vice President, Strategy and Corporate